BR112021019802A2 - Composições e métodos de uso da mesma para tratamento de doença neurodegenerativa e mitocondrial - Google Patents

Composições e métodos de uso da mesma para tratamento de doença neurodegenerativa e mitocondrial

Info

Publication number
BR112021019802A2
BR112021019802A2 BR112021019802A BR112021019802A BR112021019802A2 BR 112021019802 A2 BR112021019802 A2 BR 112021019802A2 BR 112021019802 A BR112021019802 A BR 112021019802A BR 112021019802 A BR112021019802 A BR 112021019802A BR 112021019802 A2 BR112021019802 A2 BR 112021019802A2
Authority
BR
Brazil
Prior art keywords
methods
neurodegenerative
compositions
treatment
analogues
Prior art date
Application number
BR112021019802A
Other languages
English (en)
Portuguese (pt)
Inventor
De Roulet Daniel
Johan Bartholomeus
Thomas Hertz Nicholas
Marcelo Chin Randall
Robert Devita
Shawn Johnstone
Original Assignee
Mitokinin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitokinin Inc filed Critical Mitokinin Inc
Publication of BR112021019802A2 publication Critical patent/BR112021019802A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021019802A 2019-04-03 2020-04-03 Composições e métodos de uso da mesma para tratamento de doença neurodegenerativa e mitocondrial BR112021019802A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962828995P 2019-04-03 2019-04-03
US201962879794P 2019-07-29 2019-07-29
US201962933632P 2019-11-11 2019-11-11
PCT/US2020/026732 WO2020206363A1 (en) 2019-04-03 2020-04-03 Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease

Publications (1)

Publication Number Publication Date
BR112021019802A2 true BR112021019802A2 (pt) 2021-12-07

Family

ID=72666280

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019802A BR112021019802A2 (pt) 2019-04-03 2020-04-03 Composições e métodos de uso da mesma para tratamento de doença neurodegenerativa e mitocondrial

Country Status (11)

Country Link
US (2) US20220162215A1 (https=)
EP (1) EP3947390A4 (https=)
JP (1) JP2022527025A (https=)
KR (1) KR20220004068A (https=)
CN (1) CN114026093A (https=)
AU (1) AU2020253561A1 (https=)
BR (1) BR112021019802A2 (https=)
CA (1) CA3135755A1 (https=)
IL (1) IL286767A (https=)
MX (1) MX2021012129A (https=)
WO (1) WO2020206363A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018290225A1 (en) 2017-06-21 2020-01-23 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
US20250129080A1 (en) * 2021-08-20 2025-04-24 Mitokinin, Inc. Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
WO2023023671A1 (en) * 2021-08-20 2023-02-23 Mitokinin, Inc. Compositions and methods for treatment of neurodegenerative and mitochondrial disease
WO2024040266A2 (en) * 2022-08-19 2024-02-22 Mitokinin, Inc. Disubstituted benzoimidazole and indole analogs as modulators of pink1
EP4620957A1 (en) * 2024-03-22 2025-09-24 Eberhard Karls Universität Tübingen Imidazo[4,5-b]pyridin-7-amine compounds binding aurora kinase a and uses thereof
CN118290348A (zh) * 2024-03-22 2024-07-05 诚达药业股份有限公司 一种4-氯吡咯并嘧啶类化合物或其衍生物的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
CN101282761A (zh) * 2005-08-04 2008-10-08 西特里斯药业公司 作为sirtuin调节剂的苯并咪唑衍生物
ES2412384T3 (es) * 2006-07-18 2013-07-11 Astellas Pharma Inc. Derivado de aminoindano o sal del mismo
WO2014124458A1 (en) * 2013-02-11 2014-08-14 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
EP2818472A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators
ES2919024T3 (es) * 2014-02-11 2022-07-21 Mitokinin Inc Composiciones y procedimientos que utilizan las mismas para el tratamiento de enfermedades neurodegenerativas y mitocondriales
JP2018537502A (ja) * 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
WO2018065365A1 (en) * 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
WO2018106818A1 (en) * 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
AU2018290225A1 (en) * 2017-06-21 2020-01-23 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
CN115515682B (zh) * 2020-02-21 2024-06-21 麦托吉宁公司 用于治疗神经退行性疾病和线粒体疾病的组合物及其使用方法

Also Published As

Publication number Publication date
US20250250276A1 (en) 2025-08-07
MX2021012129A (es) 2022-01-31
KR20220004068A (ko) 2022-01-11
JP2022527025A (ja) 2022-05-27
IL286767A (en) 2021-12-01
EP3947390A1 (en) 2022-02-09
EP3947390A4 (en) 2022-11-30
CA3135755A1 (en) 2020-10-08
CN114026093A (zh) 2022-02-08
WO2020206363A1 (en) 2020-10-08
AU2020253561A1 (en) 2021-12-02
US20220162215A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
BR112021019802A2 (pt) Composições e métodos de uso da mesma para tratamento de doença neurodegenerativa e mitocondrial
ECSP22041839A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
BR112022010349A2 (pt) Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
CY1121826T1 (el) Προφαρμακα καρβιντοπας και l-ντοπας και η χρηση τους στην αγωγη της νοσου parkinson
CL2021001406A1 (es) Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso.
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
MX2021002322A (es) Nuevos metodos.
MX384908B (es) Rad1901 para usarse en el tratamiento de cáncer en sujetos con cáncer positivo a receptor de estrógeno alfa resistente a farmaco.
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
BR112019003579A2 (pt) Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos
CO2017000346A2 (es) Anticuerpos de unión a protofibrillas aβ
MX2018013472A (es) Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
BR112023018472A2 (pt) Composições de psilocibina, métodos de produção e métodos de uso das mesmas
MX2018016419A (es) Derivados de n-(sustituida-fenil)-sulfonamida como inhibidores de quinasa n-(sustituida-fenil)-sulfonamida.
MX2021005839A (es) Antagonistas del receptor de adenosina aminotriazolopirimidina y aminotriazolopirazina sustituidos, composiciones farmaceuticas y su uso.
MX389962B (es) Metodos para tratar trastornos mitocondriales y metabolicos.
SG11202011010YA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
SG11202011018PA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
BR112021019055A2 (pt) Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
MY197171A (en) Compounds and methods for the treatment of parasitic diseases
BR112018069782A2 (pt) composição farmacêutica de dapagliflozina
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
NZ772009A (en) Use of riluzole prodrugs to treat alzheimer’s disease

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements